Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sarepta Therapeutics Inc (SRPT) Financials: Revenue, Profit and Cash Flow
Sarepta Therapeutics reported revenue of $2.20B for the fiscal year ended Dec 31, 2025, up 15.6% from the year before. That year, net income was -$713.41M with a net margin of -32.5%, operating cash flow was -$205.48M and free cash flow was -$307.45M. The quarter ended Sep 30, 2026 had revenue of $381.35M and net income of -$28.46M.
Revenue and Margins
The operating margin was -31.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $5.42M, a compound annual rate of 94.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.20B | +15.6% | 100.0% | -31.8% | -32.5% |
| Dec 2024 | $1.90B | +53.0% | 100.0% | 11.5% | 12.4% |
| Dec 2023 | $1.24B | +33.3% | 100.0% | -21.5% | -43.1% |
| Dec 2022 | $933.01M | +32.9% | 100.0% | -57.5% | -75.4% |
| Dec 2021 | $701.89M | +30.0% | 100.0% | -65.5% | -59.7% |
| Dec 2020 | $540.10M | +41.8% | 100.0% | -104.5% | -102.6% |
| Dec 2019 | $380.83M | +26.5% | 100.0% | -185.3% | -187.8% |
| Dec 2018 | $301.03M | +94.7% | 100.0% | -114.1% | -120.2% |
| Dec 2017 | $154.58M | +2751.6% | 100.0% | -111.0% | -32.8% |
| Dec 2016 | $5.42M | N/A | 100.0% | -4920.3% | -4930.2% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M | $540.10M | $380.83M | $301.03M | $154.58M | $5.42M |
| Gross profit | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M | $540.10M | $380.83M | $301.03M | $154.58M | $5.42M |
| Research and development | $1.52B | $804.52M | $877.39M | $877.09M | $771.18M | $722.34M | $734.15M | $401.84M | $166.71M | $188.27M |
| Operating income | -$699.78M | $218.08M | -$267.82M | -$536.20M | -$459.71M | -$564.16M | -$705.56M | -$343.63M | -$171.64M | -$266.73M |
| Net income | -$713.41M | $235.24M | -$535.98M | -$703.49M | -$418.78M | -$554.13M | -$715.08M | -$361.92M | -$50.69M | -$267.26M |
| EBITDA | -$674.57M | $298.50M | -$88.37M | -$522.66M | -$380.93M | -$526.15M | -$689.38M | N/A | -$41.42M | -$261.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $381.35M | $401.25M | $730.80M | $442.93M | $399.36M | $611.09M | $744.86M | $658.41M | $467.17M | $362.93M | $413.46M | $396.78M |
| Gross profit | $381.35M | $401.25M | $730.80M | $442.93M | $399.36M | $611.09M | $744.86M | $658.41M | $467.17M | $362.93M | $413.46M | $396.78M |
| Operating income | -$9.04M | $13.29M | $358.43M | -$411.58M | -$103.39M | $115.58M | -$300.39M | $161.68M | $22.20M | -$701.00K | $34.91M | $24.63M |
| Net income | -$28.46M | -$4.89M | $330.96M | -$282.85M | -$50.57M | $196.89M | -$447.51M | $159.05M | $33.61M | $6.46M | $36.12M | $45.66M |
Balance Sheet
As of Dec 2025, total debt of $828.97M exceeded cash and equivalents by $27.69M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424.10M |
| Current assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373.48M |
| Cash and equivalents | $801.28M | $1.10B | $428.43M | $966.78M | $2.12B | $1.50B | $835.08M | $370.83M | $599.69M | $122.42M |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.80M | $518.75M | $87.41M |
| Short-term debt | $0 | $13.47M | $105.48M | $0 | $271.70M | $193.55M | $7.85M | $134.09M | $6.17M | $10.11M |
| Long-term debt | $828.97M | $1.14B | $1.13B | $1.54B | $1.10B | $992.49M | $681.90M | $420.55M | $424.88M | $6.04M |
| Shareholder equity | $1.14B | $1.53B | $859.34M | $384.95M | $928.01M | $761.76M | $818.19M | $1.03B | $789.22M | $336.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.17B | $3.19B | $3.18B | $3.35B | $3.49B | $3.68B | $3.47B | $3.96B | $3.60B | $3.42B | $3.22B | $3.26B |
| Total liabilities | $1.64B | $1.66B | $1.67B | $2.21B | $2.17B | $2.32B | $2.32B | $2.44B | $2.38B | $2.35B | $2.26B | $2.41B |
| Cash and equivalents | $472.76M | $571.15M | $464.45M | $801.28M | $613.08M | $510.60M | $240.87M | $1.10B | $197.85M | $383.62M | $427.29M | $428.43M |
| Shareholder equity | $1.53B | $1.53B | $1.51B | $1.14B | $1.32B | $1.36B | $1.14B | $1.53B | $1.22B | $1.08B | $961.19M | $859.34M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$205.48M | -$205.79M | -$500.99M | -$325.35M | -$443.17M | $107.47M | -$456.46M | -$388.66M | -$232.00M | -$245.82M |
| Capital expenditures | $101.97M | $136.96M | $76.11M | $30.82M | $38.49M | $82.20M | $59.63M | $61.16M | $12.00M | $5.34M |
| Free cash flow | -$307.45M | -$342.74M | -$577.10M | -$356.17M | -$481.66M | $25.26M | -$516.09M | -$449.82M | -$244.00M | -$251.16M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $286.31M | $240.60M | N/A | $0 | $0 |
| Share repurchases | $27.40M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $69.64M | $755.56M | -$165.80M | -$1.05B | $495.41M | -$121.72M | $286.73M | -$370.49M | -$178.81M | -$90.19M |
| Financing cash flow | -$168.34M | $124.81M | $125.00M | $232.51M | $561.57M | $682.32M | $642.55M | $530.15M | $888.08M | $378.13M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $59.97M | $197.07M | -$202.68M | $131.21M | -$14.59M | $261.34M | -$583.44M | $92.05M | -$70.70M | $14.94M | -$242.08M | -$54.66M |
| Capital expenditures | $2.93M | $555.00K | $2.08M | $3.59M | $22.93M | $31.80M | $43.65M | $38.08M | $37.26M | $29.17M | $32.44M | $19.04M |
| Free cash flow | $57.03M | $196.51M | -$204.76M | $127.61M | -$37.52M | $229.54M | -$627.09M | $53.96M | -$107.96M | -$14.22M | -$274.52M | -$73.70M |
Frequently Asked Questions About SRPT
What is Sarepta Therapeutics' annual revenue?
Sarepta Therapeutics reported revenue of $2.20B for the fiscal year ended Dec 31, 2025.
How fast is Sarepta Therapeutics' revenue growing?
Revenue was up 15.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 33.1%.
Is Sarepta Therapeutics profitable?
No. Sarepta Therapeutics reported net income of -$713.41M for the fiscal year ended Dec 31, 2025, with a net margin of -32.5%.
How much free cash flow does SRPT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$205.48M minus capital expenditures of $101.97M produced free cash flow of -$307.45M.
How much debt does Sarepta Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $828.97M, short-term debt of $0 and cash and equivalents of $801.28M.
SRPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors